Skip to main content

Champions Oncology to Announce First Quarter Financial Results on Thursday, September 8, 2022

HACKENSACK, NJ / ACCESSWIRE / September 6, 2022 / Champions Oncology, Inc. (NASDAQ: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the first quarter ended July 31, 2022, on Thursday, September 8, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 618777. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 46511, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/714836/Champions-Oncology-to-Announce-First-Quarter-Financial-Results-on-Thursday-September-8-2022

Recent Quotes

View More
Symbol Price Change (%)
AMZN  218.56
-3.47 (-1.56%)
AAPL  258.67
-4.10 (-1.56%)
AMD  229.25
-8.78 (-3.69%)
BAC  50.84
-0.69 (-1.33%)
GOOG  254.08
+2.74 (1.09%)
META  730.45
-2.82 (-0.39%)
MSFT  522.43
+4.77 (0.92%)
NVDA  179.32
-1.84 (-1.02%)
ORCL  272.25
-2.90 (-1.06%)
TSLA  433.85
-8.75 (-1.98%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.